Common Drug Review *

Submission Status

Product: Fosavance

Generic Name: alendronate sodium /cholecalciferol

Manufacturer: Merck Frosst Canada Ltd.

Submission Type: New

Date Submission Received: 2006-Mar-27 **Date NOC Issued:** 2006-Feb-03

Targeted CEDAC Meeting: 2006-Jul-26 **Priority Review Granted:** Not requested

	Phase	Target Time (Business Days)	Target Date**	Actual CDR Date	Comments
1	Submission Deemed Complete	5	2006-Apr-03	2006-Apr-03	
2	CDR Reviewers' Reports Completed • Reviewers selected and contracted • Literature search and selection completed • Systematic review of clinical data completed • Critical appraisal of pharmacoeconomic (PE) data completed • Clinical and PE reports written • Reports edited and finalized • Reviewers' reports sent to manufacturer	45	2006-Jun-07	2006-Jun-02	Clarification requested May 23, 2006. Clarification received May 26, 2006.
3	Comments from Manufacturer on Reviewers' Reports Received by CDR	7	2006-Jun-16	2006-Jun-13	Due date for manufacturer's comments June 13, 2006.
4	Reviewers' Reply to Manufacturer's Comments Completed	7	2006-Jun-27	2006-Jun-21	Due date for Reviewer's Reply June 22, 2006.
5	CEDAC Brief Completed and Sent to CEDAC Members	5	2006-Jul-12	2006-Jul-12	
6	CEDAC Meeting		2006-Jul-26	2006-Jul-26	
7	CEDAC Recommendation and Reasons for Recommendation Sent to Drug Plans, ACP and Manufacturer	5	2006-Aug-02	2006-Aug-02	
8	Embargo Period*** Manufacturers may make a Request for Reconsideration and Drug Plans may make a Request for Clarification of the Recommendation and Reasons for Recommendation	10	2006-Aug-17	2006-Aug-23	Manufacturer requested extension of Embargo Period to August 23, 2006. Request granted. Request for Reconsideration received August 22, 2006.
9 (a)	Final Recommendation sent to Drug Plans, ACP, and Manufacturer (No Requests for Clarification are made AND no Request for Reconsideration is made or Request for Reconsideration is Resolved)	5			
	OR				
9 (b)	Clarification and Final Recommendation sent to Drug Plans, ACP, and Manufacturer (Clarification Requested, no Request for Reconsideration made)	5			
	OR				
9 (c)	Placed on CEDAC Agenda For Reconsideration (At Manufacturer's request)	25 Depends on Meeting Dates	2006-Sep-20	2006-Sep-20	
10	Final Recommendation sent to Drug Plans, ACP, and Manufacturer	5	2006-Sep-27	2006-Sep-27	Notice of Final Recommendation issued.

* Refer to the Procedure for Common Drug Review on the Common Drug Review section of www.cadth.ca for more details.
** The CDR review process is initiated AFTER a submission is deemed complete. The target dates for this report are based on the CEDAC meeting schedule, which is posted on www.cadth.ca.
*** The Recommendation and Reasons for Recommendation are to be held in confidence and not acted upon until after the CDR Directorate has issued the notice of Final Recommendation.